Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00592670 · ClinicalTrials.gov registry record · NA

Hypoglycemia Associated Autonomic Failure in Type 1 DM

A NA study of Type 1 Diabetes, sponsored by Vanderbilt University.

Completed
Registry status
NA
Development phase
48
Enrollment target
1
Study location

NCT00592670: Completed NA study of Type 1 Diabetes, sponsored by Vanderbilt University.

NCT00592670 is a NA study of Type 1 Diabetes that has completed, run by Vanderbilt University. The registered enrollment target is 48 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00592670, a NA study of Type 1 Diabetes, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
NA
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

It is unclear what effect selective serotonin reuptake inhibitors (SSRIs) have on hypoglycemia. Thus, the American Hospital Formulary Service recommends careful monitoring of blood glucose levels in all patients with diabetes initiating or discontinuing SSRIs (Katz et al., 1996). Because of the increased prevalence of depression in those with diabetes, it is critical to discover what affect the antidepressant therapy may have on counterregulatory responses to hypoglycemia. This study hypothesizes that chronic administration of SSRIs may result in a blunted counterregulatory response to hypoglycemia, thereby leaving individuals more susceptible to hypoglycemia.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Fluoxetine

Study Locations (1)

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2005-03
Est. Completion 2008-10
Phase NA
Vanderbilt University

430 total trials

What the finished NCT00592670 record still lists

NCT00592670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00592670 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT00592670 about?

NCT00592670 is a clinical study titled "Hypoglycemia Associated Autonomic Failure in Type 1 DM". It is unclear what effect selective serotonin reuptake inhibitors (SSRIs) have on hypoglycemia. Thus, the American Hospital Formulary Service recommends careful monitoring of blood glucose levels in all patients with diabetes initiating or discontinuing SSRIs (Katz et al., 1996). Because of the incr...

What is the current status of trial NCT00592670?

This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2005-03. Estimated completion is 2008-10.

What conditions does trial NCT00592670 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT00592670?

The interventions under investigation include: Placebo (DRUG), Fluoxetine (DRUG).

Who is sponsoring clinical trial NCT00592670?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00592670 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00592670's enrollment target sits among peer trials

48 93rd of 198 higher than 105 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00592670, the US trial registry maintained by the National Library of Medicine. NCT00592670 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.